Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of GI Events in TAK-788 Treated EGFR Exon 20 Insertion NSCLC
NCT04576208Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
Phase 2, randomised, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) of >=Grade 3 Diarrhea Occurring During the First 4 Cycles of TAK-788 Dosing. Planned start Nov 2020; status: withdrawn.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04576208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576208.